- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03737565
Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (RETO 320)
January 20, 2022 updated by: Fundación EPIC
Prospective, Multicenter and Observational Registry for the Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (Reto 320 Study)
This prospective registry is intended to evaluate the safety and efficacy of the Optimax® stent.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This prospective registry is intended to evaluate the safety and efficacy of the Optimax® stent in de novo coronary lesions with reference diameter ≥ 3.0 mm and Length ≤ 20 mm.
Study Type
Observational
Enrollment (Anticipated)
350
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fundación EPIC
- Phone Number: +34987876135
- Email: admin@fundacionepic.org
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall d'Hebron
-
Cáceres, Spain, 10003
- Not yet recruiting
- Hospital San Pedro de Alcantara
-
León, Spain, 24080
- Recruiting
- Hospital Universitario de Leon
-
Lleida, Spain, 25198
- Not yet recruiting
- Hospital Universitari Arnau de Vilanova
-
-
Badajoz
-
Mérida, Badajoz, Spain, 06800
- Not yet recruiting
- Hospital de Merida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with de novo coronary lesion treated with Optimax® stent, reference diameter = 3.0 mm and length ≤ 20 mm.
Description
Inclusion Criteria:
- Patients with age ≥ 18 years old.
- Patients with de novo coronary lesion treated with Optimax® stent, reference diameter = 3.0 mm and length ≤ 20 mm.
- Informed consent signed.
Exclusion Criteria:
- Refusal of the patient to participate at the study.
- Treatment of other injuries that do not meet the conditions (3x20).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Coronary Artery Disease
|
Percutaneous coronary intervention with Optimax stent®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety. The number of composite events of cardiac.
Time Frame: 6 and 12 month
|
The number of composite events of cardiac death, myocardial infarction (MI) and stent thrombosis (Academic Research Consortium definitive/probable).
|
6 and 12 month
|
Efficacy: Incidence of clinically driven target lesion revascularization (TLR).
Time Frame: 6 and 12 month
|
Incidence of clinically driven target lesion revascularization (TLR).Defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.
|
6 and 12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All death.
Time Frame: 6 and 12 month
|
Systemic embolism, Major bleeding event (BARC ≥ 2).
|
6 and 12 month
|
Cardiac death.
Time Frame: 6 and 12 month
|
Cardiac death.
|
6 and 12 month
|
Target Vessel revascularization.
Time Frame: 6 and 12 month
|
Target Vessel revascularization.
|
6 and 12 month
|
Target lesion revascularization.
Time Frame: 6 and 12 month
|
Target lesion revascularization.
|
6 and 12 month
|
Stent thrombosis (ARC definite/probable).
Time Frame: 6 and 12 month
|
Stent thrombosis (ARC definite/probable).
|
6 and 12 month
|
Major bleeding event (BARC type 2-5).
Time Frame: 6 and 12 month
|
Major bleeding event (BARC type 2-5).
|
6 and 12 month
|
Stroke.
Time Frame: 6 and 12 month
|
Stroke.
|
6 and 12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lopez-Minguez JR, Nogales-Asensio JM, Romani S, Rivero-Crespo F, Aragon-Extremera VM, Jimenez-Mazuecos JM, Carrasco F, Oteo-Dominguez JF, Bosa-Ojeda F, Gomez-Hospital JA. TIOMAX: A Spanish Multicenter Registry of the real-world use of the TItanium OptiMAX(R) biostent: TIOMAX: Registro Espanol Multicentrico Del Biostent De Titanio OptiMAX(R) En La Vida Real. Catheter Cardiovasc Interv. 2018 Aug 1;92(2):261-268. doi: 10.1002/ccd.27326. Epub 2017 Sep 30.
- Karjalainen PP, Nammas W, Ylitalo A, de Bruyne B, Lalmand J, de Belder A, Rivero-Crespo F, Kervinen K, Airaksinen JKE. Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial. Int J Cardiol. 2016 Nov 1;222:275-280. doi: 10.1016/j.ijcard.2016.07.267. Epub 2016 Aug 1.
- Colkesen EB, Eefting FD, Rensing BJ, Suttorp MJ, Ten Berg JM, Karjalainen PP, Van Der Heyden JA. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives. Minerva Cardioangiol. 2015 Feb;63(1):21-9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 17, 2019
Primary Completion (Anticipated)
March 15, 2022
Study Completion (Anticipated)
April 15, 2022
Study Registration Dates
First Submitted
November 8, 2018
First Submitted That Met QC Criteria
November 8, 2018
First Posted (Actual)
November 9, 2018
Study Record Updates
Last Update Posted (Actual)
January 24, 2022
Last Update Submitted That Met QC Criteria
January 20, 2022
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RETO 320
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Optimax stent®
-
Hyeon-Cheol GwonTerumo Corporation; Meril Life Sciences Pvt. Ltd.UnknownIschemic Heart DiseaseKorea, Republic of
-
Can Tho Stroke International Services HospitalAcandis GmbHCompletedIschemic Stroke | Stent Stenosis | Intracranial AtherosclerosisVietnam
-
Swiss Vision NetworkActive, not recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Primary Open Angle
-
Chinese University of Hong KongTerminated
-
Hospital Universitari Vall d'Hebron Research InstituteB.Braun Surgical SACompleted
-
Cordis CorporationCompletedSuperficial Femoral Artery DiseaseUnited States
-
Cook Research IncorporatedCompletedAortic Aneurysm, AbdominalUnited States
-
W.L.Gore & AssociatesCompleted
-
Cook Research IncorporatedCompleted